Addressing large, unmet global markets with innovative proprietary products More »
Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »
Identifying early-stage companies with potential to increase value for shareholders More »
OPKO Health Reports 2018 Fourth Quarter Business Highlights and Financial Results more »
OPKO Health to Announce Fourth Quarter 2018 Financial Results on February 27, 2019 more »
OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes more »
OPKO Health is an opportunistic research and development company that targets large, high-growth markets.
FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease click here »